Recombinant Human P2Y purinoceptor 14 (P2RY14)

What is P2Y purinoceptor 14 and how does it differ from other purinergic receptors?

P2Y purinoceptor 14 (P2RY14) belongs to the P2Y purinoceptor subfamily, a group of eight molecularly defined G-protein coupled receptors that respond to nucleotides and nucleotide sugars. Unlike other P2Y receptors that primarily respond to adenine nucleotides, P2RY14 is distinctively activated by UDP and UDP-sugars, including UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine. P2RY14 belongs to the P2Y12-receptor subfamily and signals through Gi protein, inhibiting adenylyl cyclase activity and decreasing intracellular cAMP levels .

What are the principal natural ligands of P2RY14 and their relative potencies?

P2RY14 is potently activated by UDP and a class of carbohydrates known as UDP-sugars. Historically considered primarily a nucleotide sugar-activated receptor, recent discoveries indicate that UDP is approximately 5-fold more potent than UDP-sugars at the P2RY14 receptor, suggesting it may be the most important agonist under certain physiological conditions . Among UDP-sugars, UDP-glucose, UDP-galactose, and UDP-glucuronic acid exhibit similar potencies, while UDP-N-acetylglucosamine is approximately 10-fold less potent . These ligands activate the receptor with EC50 values in the nanomolar range, with UDP-glucose demonstrating an EC50 of approximately 82-107 nM in heterologous expression systems .

Where is P2RY14 primarily expressed in humans?

P2RY14 is relatively broadly expressed in human tissues. It is prominently associated with immune and inflammatory cells as well as with many epithelia . Significant expression has been documented in hematopoietic stem/progenitor cells, where it plays a role in homeostasis . In the nervous system, P2RY14 is expressed in Schwann cell precursors (SCPs) and Schwann cells (SCs), including satellite glial cells . This widespread distribution underscores its potential involvement in diverse physiological processes including inflammation, immune response, and glial cell function.

What is the primary signaling pathway activated by P2RY14?

P2RY14 primarily signals through the inhibitory G-protein (Gi) pathway. Upon activation, P2RY14 couples to Gi-family G-proteins, leading to inhibition of adenylyl cyclase and subsequent decrease in intracellular cAMP levels . This signaling mechanism has been confirmed in multiple cell types, including HEK293 cells and C6 rat glioma cells stably expressing P2RY14. The involvement of Gi is further validated by the complete abolishment of P2RY14-mediated responses following pertussis toxin treatment, which ADP-ribosylates and inactivates Gi proteins .

What secondary signaling pathways can be activated downstream of P2RY14?

Beyond cAMP inhibition, P2RY14 activation can trigger additional signaling cascades. In RBL-2H3 mast cells expressing P2RY14, UDP-glucose promotes calcium mobilization in a pertussis toxin-sensitive manner, indicating Gi-dependent calcium signaling . Additionally, P2RY14 activation leads to phosphorylation of ERK1/2, demonstrating coupling to MAP kinase signaling pathways . In functional contexts, P2RY14 stimulation in RBL-2H3 cells results in β-hexosaminidase release, suggesting a role in degranulation responses. These diverse signaling outputs highlight the multifaceted nature of P2RY14 signal transduction beyond simple cAMP inhibition.

How does the KDKE motif contribute to ligand recognition by P2RY14?

Between transmembrane helices 2 and 7 of P2RY14, researchers have identified a conserved salt bridging chain (K2.60-D2.64-K7.35-E7.36, referred to as the KDKE motif) that plays a crucial role in ligand discrimination . This structural element helps the receptor distinguish between different UDP-sugars, including UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine . Molecular dynamics simulations coupled with functional studies have revealed that UDP-glucose might activate the receptor by bridging transmembrane helices 2 and 7, with the KDKE chain serving as a critical recognition element. Interestingly, this KDKE chain has been identified as a conserved functional motif for sugar binding in both P2RY14 and P2Y purinoceptor 12 (P2Y12) .

What expression systems are most suitable for recombinant P2RY14 studies?

Several expression systems have proven effective for studying recombinant P2RY14. HEK293 cells stably expressing P2RY14 using retrovirus expression systems have successfully demonstrated robust receptor function, with UDP-glucose promoting concentration-dependent inhibition of forskolin-stimulated cAMP accumulation . C6 rat glioma cells have also served as an excellent background for P2RY14 expression, offering robust inhibitory effects on cAMP levels in response to UDP-glucose with EC50 values around 107 nM . When selecting an expression system, researchers should consider the endogenous expression of other purinergic receptors that might complicate data interpretation. Cell lines that naturally express P2RY14, such as RBL-2H3 mast cells, can also be valuable for studying physiologically relevant signaling in a native context .

What functional assays are most appropriate for measuring P2RY14 activity?

Multiple assay platforms can effectively measure P2RY14 activity:

• cAMP assays: Measuring inhibition of forskolin-stimulated cAMP accumulation provides a direct readout of receptor activity through its primary Gi-coupled pathway. This approach has been successfully employed in both intact cells and membrane preparations .

• Calcium mobilization assays: Although not the primary pathway, P2RY14 activation can lead to calcium responses in certain cell types, providing an alternative readout system. In RBL-2H3 mast cells, UDP-glucose promotes concentration-dependent calcium mobilization that is blocked by pertussis toxin .

• ERK1/2 phosphorylation: Measuring activation of MAP kinase pathways through phosphorylation of ERK1/2 can provide insights into downstream signaling events triggered by P2RY14 activation .

• Functional cellular responses: Cell-type specific assays such as β-hexosaminidase release from RBL-2H3 cells or assessment of Schwann cell precursor self-renewal can provide physiologically relevant measures of receptor function .

What pharmacological tools are available for studying P2RY14?

Several important pharmacological tools exist for P2RY14 research:

• Agonists: Natural agonists include UDP and UDP-sugars (UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine) . Additionally, synthetic agonists like MRS2690 offer selective activation of P2RY14 .

• Antagonists: PPTN (4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid hydrochloride) is a highly selective P2RY14 inhibitor useful for blocking receptor function .

• Signaling pathway modulators: Pertussis toxin serves as an important tool to confirm Gi-dependent signaling by inactivating Gi proteins through ADP-ribosylation .

When designing experiments, researchers should consider that UDP-sugars are subject to breakdown by ecto-nucleotide pyrophosphatases but are not good substrates for ecto-nucleotidases that inactivate extracellular nucleotide agonists. This distinct metabolic profile means that the kinetics of UDP-glucose metabolism differ markedly from those of ATP, potentially affecting experimental outcomes .

How can researchers distinguish between P2RY14 and other P2Y receptor signaling in systems with multiple purinergic receptors?

Distinguishing P2RY14 activity from other P2Y receptors requires a multifaceted approach:

What is known about the structural basis of agonist binding to P2RY14?

Molecular modeling and functional studies have provided insights into P2RY14 agonist binding:

UDP-glucose binds to an extracellular pocket involving transmembrane (TM) helices 2 and 7, serving as an intramolecular "glue" attaching to TM6 and TM7 to activate the receptor . The UDP-glucose-induced conformational changes primarily affect TM6 and TM7, similar to agonist-induced changes observed in the related P2Y12 receptor . Between TM2 and TM7, the conserved KDKE salt bridging chain (K2.60-D2.64-K7.35-E7.36) plays a crucial role in distinguishing different UDP-sugars . Molecular dynamics simulations integrated with functional studies have identified the precise uridine diphosphate (UDP)-sugar-binding site on P2RY14 and revealed the molecular interactions responsible for receptor activation .

What role does P2RY14 play in Schwann cell biology and neuropathology?

P2RY14 serves as a critical regulator of Schwann cell precursor (SCP) self-renewal, Schwann cell (SC) proliferation, and neurofibroma initiation . In SCPs, P2RY14 signaling through Gi inhibits adenylate cyclase, decreasing cAMP levels and promoting self-renewal. Knockout of P2RY14 in mouse models decreased SC proliferation, improved nerve Remak bundle morphology, and decreased tumor initiation in neurofibroma models . P2RY14 inhibition with PPTN decreases mouse SCP self-renewal through modulation of cAMP, suggesting pharmacological targeting of this receptor could have therapeutic implications for neurofibroma and potentially other Schwann cell-related pathologies .

What are common pitfalls in P2RY14 experimental design and how can they be addressed?

When studying P2RY14, researchers should be aware of several potential experimental challenges:

• Overlapping receptor expression: Many cell types express multiple P2Y receptors that respond to similar ligands. Always include appropriate controls such as selective antagonists or genetic knockdown approaches to confirm P2RY14-specific effects.

• Nucleotide contamination: Commercial UDP-sugar preparations may contain UDP contamination, which is more potent at P2RY14. High-quality, purified ligands are essential for accurate potency determinations .

• Ectoenzyme activity: Cell surface enzymes can metabolize nucleotides and nucleotide sugars, affecting ligand availability. Consider the differential metabolism of UDP versus UDP-sugars when interpreting kinetic response data .

• Pertussis toxin controls: Always include pertussis toxin controls to verify the Gi-dependence of observed responses and distinguish them from parallel signaling pathways .

• Receptor reserve considerations: In recombinant systems with high expression levels, apparent potencies may be influenced by receptor reserve. Consider this possibility when comparing results across different expression systems or with native receptor expression.

How can P2RY14 knockout or knockdown models be effectively utilized?

P2RY14 knockout or knockdown models provide powerful tools for understanding receptor function:

• P2RY14-knockout mice are now available and have been used to demonstrate the receptor's role in vivo, showing increased survival, decreased SC proliferation, improved nerve Remak bundle morphology, and decreased tumor initiation in neurofibroma models .

• siRNA approaches targeting P2RY14 have been successfully employed in cell lines and in mouse uterus, providing a flexible approach for tissue-specific receptor knockdown .

• When using knockout or knockdown approaches, researchers should consider potential compensatory mechanisms that might emerge in chronic absence of receptor expression. Acute pharmacological inhibition with selective antagonists like PPTN can complement genetic approaches by revealing immediate receptor functions without triggering compensatory adaptations .

• In heterologous expression systems, empty vector controls are essential for distinguishing receptor-specific from non-specific effects, as demonstrated in studies using HEK293 and C6 glioma cells .